The protection of chimpanzees against hepatitis B viral infection using a recombinant yeast-derived hepatitis B surface antigen.
In order to determine the efficacy of the SmithKline Biologicals recombinant DNA yeast-derived hepatitis B vaccine in inducing protection against hepatitis B infection, two chimpanzees were injected intramuscularly with 20 micrograms according to a 0-, 1-, and 2-month schedule. After the second dose, the vaccinated animals already showed a significant antibody response. One month after the last injection, the animals were challenged with hepatitis B virus. The vaccinated animals were protected while the two unvaccinated controls showed all signs of hepatitis B infection. One year after vaccination, antibodies remained high and were comparable with levels produced by plasma-derived vaccines.
Schellekens
H
H
Primate Center TNO, Rijswijk, The Netherlands.
de Reus
A
A
Peetermans
J H
JH
van Eerd
P A
PA
D000818:Animals; D000941:Antigens / Q000627:therapeutic use*; D004274:DNA, Recombinant / Q000276:immunology; D005260:Female; D006509:Hepatitis B / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000276:immunology; D006514:Hepatitis B Surface Antigens / Q000235:genetics / Q000276:immunology*; D002679:Pan troglodytes / Q000276:immunology*; D012441:Saccharomyces cerevisiae / Q000235:genetics; D013997:Time Factors; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000627:therapeutic use*
D000941:Antigens; D004274:DNA, Recombinant; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D014614:Vaccines, Synthetic